AbbVie (ABBV) EBT Growth (3y) (2015 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBT Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
79.52% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
88.09% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
29.81% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-43.56% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-15.40% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
25.67% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-20.34% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
5.36% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
| Mar 31, 2026 |
29.81% |
| Dec 31, 2025 |
-3.46% |
| Sep 30, 2025 |
-45.46% |
| Jun 30, 2025 |
9.52% |
| Mar 31, 2025 |
-30.41% |
| Dec 31, 2024 |
-36.28% |
| Sep 30, 2024 |
-17.33% |
| Jun 30, 2024 |
22.65% |
| Mar 31, 2024 |
-23.15% |
| Dec 31, 2023 |
41.02% |
| Sep 30, 2023 |
-7.90% |
| Jun 30, 2023 |
79.32% |
| Mar 31, 2023 |
-46.48% |
| Dec 31, 2022 |
-1.20% |
| Sep 30, 2022 |
30.04% |
| Jun 30, 2022 |
13.60% |
| Mar 31, 2022 |
24.67% |
| Dec 31, 2021 |
56.05% |
| Sep 30, 2021 |
10.13% |
| Jun 30, 2021 |
-16.70% |
| Mar 31, 2021 |
11.40% |
| Dec 31, 2020 |
-48.33% |
| Sep 30, 2020 |
6.07% |
| Jun 30, 2020 |
-31.90% |
| Mar 31, 2020 |
14.09% |
| Dec 31, 2019 |
15.44% |
| Sep 30, 2019 |
-0.22% |
| Jun 30, 2019 |
-27.25% |
| Mar 31, 2019 |
12.73% |
| Dec 31, 2018 |
-47.87% |
| Sep 30, 2018 |
18.79% |
| Jun 30, 2018 |
6.24% |
| Mar 31, 2018 |
26.07% |
| Dec 31, 2017 |
46.60% |
| Sep 30, 2017 |
45.01% |
| Jun 30, 2017 |
17.98% |
| Mar 31, 2017 |
17.50% |
| Dec 31, 2016 |
11.56% |
| Sep 30, 2016 |
16.13% |
| Jun 30, 2016 |
15.28% |
| Mar 31, 2016 |
12.75% |
| Dec 31, 2015 |
3.95% |
| Sep 30, 2015 |
0.89% |
| Jun 30, 2015 |
6.17% |
| Mar 31, 2015 |
11.54% |